AstraZeneca - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: AstraZeneca reported stronger-than-expected second-quarter earnings. It hiked its 2010 forecast for the third time, and announced a $2 billion share-buyback program. Crestor steamed forward with a 23 percent increase in second-quarter sales, fueling the company's 23 percent rise in Q2 profits, to $2.11 billion.

Highlights

  • Revenue for the second quarter increased by 1 percent at constant exchange rates (CER) to $8,178 million.
  • Core operating profit in the second quarter was $3,650 million, unchanged at CER, as lower other operating income offset increased revenue and lower operating costs.
  • Core EPS in the second quarter increased by 9 percent at CER to $1.79.
  • Reported EPS in the second quarter increased by 22 percent at CER to $1.46.
  • Crestor patent upheld by US Court in a ruling announced on 29 June 2010.
  • The Board has recommended a first interim dividend of $0.70. Target for net share repurchases is increased to $2 billion for 2010.
  • Core EPS target for the full year increased to the range of $6.35 to $6.65.

See AstraZeneca's current stock quote from CNN Money

AstraZeneca's website: http://www.astrazeneca.com/
Full earnings release: AstraZeneca release

AstraZeneca - Big Pharma's Q2 2010 Earnings Report
Read more on

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.